Jueves, 25 Febrero, 2021

Worth Watching Stock: CVS Health Corporation (NYSE:CVS)

Cris De Lacerda | 23 Febrero, 2017, 10:16

Independent Investors Inc. now owns 6,020 shares of the pharmacy operator's stock worth $535,000 after buying an additional 20 shares in the last quarter. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island. Hedge funds and other institutional investors own 81.29% of the company's stock. This is a boost from CVS Health Corporation's previous quarterly dividend of $0.43. Burke & Herbert Bank & Trust Co. now owns 6,250 shares of the pharmacy operator's stock worth $556,000 after buying an additional 21 shares in the last quarter. SRS Capital Advisors Inc. acquired a new stake in CVS Health Corporation during the fourth quarter valued at about $120,000. Volatility for the week appears to be 1.03% in conjunction with the Volatility for the month at 1.93%. Bp Plc's holdings in CVS Health Corporation were worth $8,131,000 as of its most recent filing with the SEC. Veritas Asset Management LLP now owns 4,808,477 shares of the pharmacy operator's stock worth $460,364,000 after buying an additional 439,848 shares during the period.

Atlantic Equities analysts provided their view on CVS Health Corporation (NYSE:CVS) recently. Westbourne Investment Advisors Inc. now owns 38,459 shares of the pharmacy operator's stock worth $3,422,000 after buying an additional 1,040 shares during the period.

CVS Health Corporation (NYSE:CVS) traded at an unexpectedly low level on 02/21/2017 when the stock experienced a 0.09 loss to a closing price of $79.76.

The firm's 50-day moving average price is $79.82 and its 200-day moving average price is $84.23. The Company Touched its 52-Week High on May 9, 2016 and 52-Week Low on Nov 8, 2016. The Market Capitalization of the company stands at 84.79 Billion.

Many analysts have provided their estimated foresights on CVS Health Corporation Earnings, with 22 analysts believing the company would generate an Average Estimate of $1.11. The pharmacy operator reported $1.71 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.67 by $0.04. The firm earned $46 billion during the quarter, compared to analysts' expectations of $46.56 billion. The Return on Equity (ROE) value stands at 14.7%. The company's quarterly revenue was up 11.7% compared to the same quarter previous year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, February 2nd. Investors of record on Tuesday, January 24th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Friday, January 20th. CVS Health Corporation Health Care Plans has a PEG of 1.56 alongside a PS value of 0.48 and a PB value of 2.3. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.51%. CVS Health Corporation's payout ratio is now 40.65%. Boston Partners raised its stake in shares of CVS Health Corporation by 48.3% in the third quarter. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & worldwide copyright & trademark laws. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/02/21/jonathan-c-roberts-sells-61196-shares-of-cvs-health-corporation-cvs-stock.html.

A number of research firms recently weighed in on CVS. The relative price strength of CVS Health Corporation has a negative value of -23.93 compared to overall market performance.CVS Health Corporation is having a Relative Strength Index of 55.11 which indicates the stock is not yet over sold or over bought based on the technical indicators. Finally, Guggenheim restated a "buy" rating and issued a $90.00 target price on shares of CVS Health Corporation in a research report on Wednesday, December 28th. The stock now has an average rating of "Buy" and an average target price of $95.47. They issued a "hold" rating and a $82.00 price objective on the stock.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts have a mean recommendation of 1.90 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). CVS Health Corporation presently has a consensus rating of "Buy" and an average price target of $95.47. CVS EVP & CIO GOLD STEPHEN J also sold 9,798 shares, at a stock price of $105. Following the sale, the executive vice president now owns 89,955 shares of the company's stock, valued at approximately $7,196,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names.